388 related articles for article (PubMed ID: 31999199)
41. Chemotherapy-induced febrile neutropenia (FN): healthcare resource utilization (HCRU) and costs in commercially insured patients in the US.
Flanigan JA; Yasuda M; Chen CC; Li EC
Support Care Cancer; 2024 May; 32(6):373. PubMed ID: 38777864
[TBL] [Abstract][Full Text] [Related]
42. Clostridioides difficile infection (CDI): A pan-European multi-center cost and resource utilization study, results from the Combatting Bacterial Resistance in Europe CDI (COMBACTE-CDI).
Wingen-Heimann SM; Davies K; Viprey VF; Davis G; Wilcox MH; Vehreschild MJGT; Lurienne L; Bandinelli PA; Cornely OA; Vilken T; Hopff SM; Vehreschild JJ;
Clin Microbiol Infect; 2023 May; 29(5):651.e1-651.e8. PubMed ID: 36586512
[TBL] [Abstract][Full Text] [Related]
43. Real-world annualized healthcare utilization and expenditures among insured US patients with acute intermittent porphyria (AIP) treated with hemin.
Blaylock B; Epstein J; Stickler P
J Med Econ; 2020 Jun; 23(6):537-545. PubMed ID: 31999204
[No Abstract] [Full Text] [Related]
44. Prognostic factors for severe and recurrent Clostridioides difficile infection: a systematic review.
van Rossen TM; Ooijevaar RE; Vandenbroucke-Grauls CMJE; Dekkers OM; Kuijper EJ; Keller JJ; van Prehn J
Clin Microbiol Infect; 2022 Mar; 28(3):321-331. PubMed ID: 34655745
[TBL] [Abstract][Full Text] [Related]
45. Costs and health resource use in patients with X-linked myotubular myopathy: insights from US commercial claims.
Sacks NC; Healey BE; Cyr PL; Slocomb T; James E; Beggs AH; Graham RJ
J Manag Care Spec Pharm; 2021 Aug; 27(8):1019-1026. PubMed ID: 33843254
[No Abstract] [Full Text] [Related]
46. Cost burden of Clostridioides difficile infection to the health service: A retrospective cohort study in Scotland.
Robertson C; Pan J; Kavanagh K; Ford I; McCowan C; Bennie M; Marwick C; Leanord A
J Hosp Infect; 2020 Nov; 106(3):554-561. PubMed ID: 32717202
[TBL] [Abstract][Full Text] [Related]
47. Healthcare resource utilization and costs among psoriasis patients treated with biologics, overall and by disease severity.
Murage MJ; Anderson A; Oliveria SA; Casso D; Ojeh CK; Muram TM; Merola JF; Araujo AB
J Med Econ; 2018 Aug; 21(8):745-754. PubMed ID: 29718756
[TBL] [Abstract][Full Text] [Related]
48. Risk factors and impact of Clostridium difficile recurrence on haematology patients.
Scappaticci GB; Perissinotti AJ; Nagel JL; Bixby DL; Marini BL
J Antimicrob Chemother; 2017 May; 72(5):1488-1495. PubMed ID: 28186243
[TBL] [Abstract][Full Text] [Related]
49. Clostridioides (Clostridium) difficile infection in Japanese hospitals 2008-2017: A real-world nationwide analysis of treatment pattern, incidence and testing density.
Kimura T; Stanhope S; Sugitani T
J Infect Chemother; 2020 May; 26(5):438-443. PubMed ID: 32081648
[TBL] [Abstract][Full Text] [Related]
50. Healthcare resource utilization and costs associated with patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive NSCLC in the United States.
Samuelsen C; Lim J; Golembesky A; Shrestha S; Wang L; Griebsch I
J Med Econ; 2020 Jan; 23(1):48-53. PubMed ID: 31314630
[No Abstract] [Full Text] [Related]
51. Healthcare resource utilization and costs among patients with alpha-1 antitrypsin deficiency with liver and/or lung disease: a longitudinal retrospective study in the USA.
Hagiwara M; Divino V; Munnangi S; Delegge M; Park S; Marins EG; Ren K; Strange C
J Comp Eff Res; 2024 Jun; 13(6):e230186. PubMed ID: 38696696
[No Abstract] [Full Text] [Related]
52. Burden of Clostridioides difficile infection (CDI) - a systematic review of the epidemiology of primary and recurrent CDI.
Finn E; Andersson FL; Madin-Warburton M
BMC Infect Dis; 2021 May; 21(1):456. PubMed ID: 34016040
[TBL] [Abstract][Full Text] [Related]
53. Recurrent community-acquired Clostridium(Clostridioides)difficile infection in Serbianchildren.
Predrag S; Kuijper EJ; Nikola S; Vendrik KEW; Niko R
Eur J Clin Microbiol Infect Dis; 2020 Mar; 39(3):509-516. PubMed ID: 31713000
[TBL] [Abstract][Full Text] [Related]
54. Trends in and Risk Factors for Recurrent Clostridioides difficile Infection, New Haven County, Connecticut, USA, 2015-2020.
Okafor CM; Clogher P; Olson D; Niccolai L; Hadler J
Emerg Infect Dis; 2023 May; 29(5):877-87. PubMed ID: 37081745
[TBL] [Abstract][Full Text] [Related]
55. First-line systemic treatment adherence, healthcare resource utilization, and costs in patients with gastrointestinal neuroendocrine tumors (GI NETs) in the USA.
Broder MS; Cai B; Chang E; Yan T; Benson AB
J Med Econ; 2018 Aug; 21(8):821-826. PubMed ID: 29741466
[TBL] [Abstract][Full Text] [Related]
56. Epidemiological and economic burden of Clostridium difficile in the United States: estimates from a modeling approach.
Desai K; Gupta SB; Dubberke ER; Prabhu VS; Browne C; Mast TC
BMC Infect Dis; 2016 Jun; 16():303. PubMed ID: 27316794
[TBL] [Abstract][Full Text] [Related]
57. Real-world Experience of Bezlotoxumab for Prevention of
Hengel RL; Ritter TE; Nathan RV; Van Anglen LJ; Schroeder CP; Dillon RJ; Marcella SW; Garey KW
Open Forum Infect Dis; 2020 Apr; 7(4):ofaa097. PubMed ID: 32363211
[TBL] [Abstract][Full Text] [Related]
58. Recurrent Clostridium difficile infection is associated with treatment failure and prolonged illness in cancer patients.
Abu-Sbeih H; Choi K; Tran CN; Wang X; Lum P; Shuttlesworth G; Stroehlein JR; Okhuysen PC; Wang Y
Eur J Gastroenterol Hepatol; 2019 Jan; 31(1):128-134. PubMed ID: 30339561
[TBL] [Abstract][Full Text] [Related]
59. Development and validation of a recurrent Clostridium difficile risk-prediction model.
Zilberberg MD; Reske K; Olsen M; Yan Y; Dubberke ER
J Hosp Med; 2014 Jul; 9(7):418-23. PubMed ID: 24700708
[TBL] [Abstract][Full Text] [Related]
60. Healthcare resource utilization and costs associated with venous thromboembolism in cancer patients treated with anticoagulants.
Streiff M; Milentijevic D; McCrae KR; Laliberté F; Lejeune D; Lefebvre P; Schein J; Khorana AA
J Med Econ; 2019 Nov; 22(11):1134-1140. PubMed ID: 31106638
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
